SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
出版年份 2018 全文链接
标题
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
作者
关键词
Clinical guidance, Glucose-lowering medicines, Oral glucose-lowering medicines, Prescribing tools, Risk/benefit, SGLT2 inhibitors, Therapy choice, Type 2 diabetes
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-07-23
DOI
10.1007/s13300-018-0471-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
- (2018) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- (2016) Deepson S Shyangdan et al. BMJ Open
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
- (2014) Suzanne Geerlings et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The importance of weight management in type 2 diabetes mellitus
- (2014) J. P. H. Wilding INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A Review on the Relationship between SGLT2 Inhibitors and Cancer
- (2014) Hao-Wen Lin et al. International Journal of Endocrinology
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts
- (2011) Brad C. Astor et al. KIDNEY INTERNATIONAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started